ANZICS CTG Endorsed Study
Taking advantage of the unique opportunity offered by the EPO TBI multicentre randomised controlled trial of erythropoietin (EPO) in traumatic brain injury (TBI), this substudy will investigate whether in patients with TBI: a) EPO reduces the severity, incidence, and duration of Acute Kidney Injury (AKI); b) the release of kidney injury biomarkers including NGAL will be reduced by EPO compared to those receiving placebo; c) the release of kidney injury biomarkers including NGAL will predict the occurrence, severity and duration of AKI in patients with TBI.
The EPO-TBI study provides the opportunity to evaluate the benefit of EPO as a treatment for AKI. If it is found to be beneficial, this could justify dedicated investigation of this intervention in critically ill patients at risk of AKI. Study of the biomarkers will provide unprecedented insight into their release and performance as markers of AKI and their response to therapy.
Elizabeth Moore (Chair / Project Manager), Michael Bailey, Rinaldo Bellomo, and Alistair Nichol.
ANZIC Research Centre, Monash University
606 patients – EPO-AKI; 30 patients – EPO-Biomarkers
Intensive Care Foundation (joint funding for EPO-TBI and POLAR renal substudies) $13,553.
Project Status as of June 2018
The first manuscript is close to submission.
Elizabeth Moore (mail)
NCT00987454 (EPO-TBI Study)
ACTRN12609000827235 (EPO-TBI Study)
EUDRA CT: 2011 – 005235 – 22 (EPO-TBI Study)